Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.2B
108M shares
52-week range
$28.66 – $126.38
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
15.9
EV / FCF (TTM)
123
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
www.corcept.comNo one on the platform currently holds CORT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 5,682,783 | $229.1M |
| Bridgewater Associatesas of 2026-03-31 | 38,422 | $1.5M |
No one on the platform has traded CORT yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.6% | 23.7% | 64.8% | — | — | — |
| Rev. Growth % | 12.8% | 16.6% | ||||
| Profit Margin % | 13.1% | 22.4% | 29.4% | |||
| Free Cash Flow Margin % | 18.6% | 29.9% | 34.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +33.4% on the P/E track.
At today's price, your expected annual return is +42.7% on the P/E track.
At today's price, your expected annual return is +53.0% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +36.2% | $2.06 | $1.73–$2.24 | 54.3× | 4 |
| 2027 | $1.6B | +42.8% | $4.29 | $2.38–$5.06 | 26.1× | 4 |
| 2028 | $2.2B | +37.5% | $7.12 | $3.72–$11.63 | 15.7× | 4 |
| 2029 | $2.5B | +14.1% | $8.54 | $7.62–$10.10 | 13.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.02 | $0.36 | +1383.3% |
| 2026-04-30 | $-0.11 | $-0.30 | -172.3% |
| 2026-02-24 | $0.33 | $0.20 | -39.4% |
| 2025-11-04 | $0.18 | $0.16 | -11.1% |
| 2025-07-31 | $0.23 | $0.29 | +26.1% |
| 2025-05-05 | $0.17 | $0.17 | +0.0% |
| 2025-02-26 | $0.37 | $0.26 | -29.7% |
| 2024-10-30 | $0.28 |
| $0.41 |
| +46.4% |
| $9.0B |
| — |
| HALOHalozyme Therapeutics, Inc. | $107.94 | +0.69% | $12.8B | — |
| JAZZJazz Pharmaceuticals plc | $245.87 | +0.03% | $15.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@jenbunn @cubie @itsphd @Jeremymartin007 @judgeyoung2 @ZY786 @jeremy4 @Tradermikes40 @TraderRapp @zuby34 Closed $CORT long strangle 27.5/30p 32.5/35c 0.85->0.45, -$1230 😢
View on StockTwits ↗
What does the StockTwits community think of recent S&P deletions? Most of the deletions from the top 3 indexes are merely moves to another index within the family. The most interesting is the bottom group where of the ten drops from the S&P 600, eight are removals entirely from the family. $CORT and $EAT moved up. The number of watchers for the eight drops were all less than 1000! $SPY $NKE $TTD
View on StockTwits ↗
Top 5 Buys · Sep 09, 2026 Today's scan produced 5 names. Every one in a confirmed Stage 2 Uptrend with a perfect 7/7 tech setup. $CORT is the standout on relative strength (RS 97) with strong institutional accumulation at 82. $TER with RS 93, suggesting the move is still early and the trend is healthy. $VCTR and $WAB are solid middle-of-the-pack setups with clean technicals across the board.
View on StockTwits ↗
$CORT This has the potential to create a strong near term catalyst with forced buying of up to 12mm shares over about 10 days as etfs and indexed funds rebalance. Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 https://share.google/vWrMr72VMg3dNBjEs
View on StockTwits ↗$CORT Corcept has at least 4 upcoming catalysts, any one of which could DOUBLE the stock price from today. This is what AI has to say about this: (1) Positive data from the Phase 2b MONARCH trial evaluating miricorilant in Metabolic Dysfunction-Associated Steatohepatitis (MASH) would be a massive multi-billion-dollar valuation catalyst for Corcept Therapeutics Inc (NASDAQ: CORT), likely sending the stock surging. While Corcept's current $10 billion+ market cap is anchored by its core Cushing’s and oncology portfolio, strong MASH data would officially open the door to one of the most lucrative and highly sought-after multi-billion-dollar blockbusters markets in modern pharma.
View on StockTwits ↗
$CORT Although I and many entrenched Longs here are not worried about the 14-point SP drop in the past 7 days, some new-comeres are mightily worried. Instead of losing sleep, please rember that the SP was in the 30's a year ago and there are so many positives going for the company moving forward. Just keep in mind, here we have the following B$ blockbuster drugs: - Korlym for CS, - Lifyorli for PROC, - Relacorilant for CS (2027), - Dazucorilant for ALS (2028) - Miricorilant for MASH (multi B$'s, 2028) - Nenocorilant for solid tumors (2030) CORT's SP will hit $300/sh by 2030, or be in acquired before then for north of $200. Others worth nothing: - low share count - only about 100M shares, - No debt & self-funded all clinical development, - Highly profitable and lots of cash in hand, - Mostly owned by Tutes. GLTA and cheers!
View on StockTwits ↗$CORT We have 1Q+1M left in 2026. The balance of the year and H1/2027 should be a busy one rich in catalysts: - Lifyorli sales ramp and record revenue every quarter forwards; - Relacorilant/CS approval in Nov or Dec 2026; - Miricorilant/MASH P2b trial completion & readout by EOY 2026; - Dazucorilant/ALS dose titration trial completion by EOY 2026; - Dazucorilant/ALS P3 trial initiation in H1 2026; - Miricorilant/MASH P3 trial initiation in H1 2026; Each of the the above catalysts should move SP up by a noticeable gap. Cheers.
View on StockTwits ↗
Corcept Therapeutics ($CORT) Stock Hub 2026: Revenue Up 32% And Back To Profit, What Does The December 17 Cushing’s Decision Add? https://www.merlintrader.com/corcept-therapeutics-cort-stock-hub-2026/
View on StockTwits ↗$CORT Big Pharma is starving for product and pipeline. Look at last weeks Journal article. Meanwhile, CORT just had second best cancer launch of all time with a drug with IP that goes out to at least 2040. CORT also has rich very late stage pipeline: MASH, ALS, ONCOLOGY (various), CUSHINGS Look for buyout in $200 range 6-9 months. I am loading up sub $130….bargain territory https://www.wsj.com/health/pharma/pharma-industry-stares-down-biggest-patent-cliff-in-decades-2d96c4cd?st=JRW4wy&reflink=article_email_share
View on StockTwits ↗$CORT Profit taking and manipulation by shorties and MM's.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.